Informace o publikaci
Duální inhibice AT1 receptoru pro angiotenzin II a neprilysinu aneb sacubitril-valsartan
| Autoři | |
|---|---|
| Rok publikování | 2019 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | Interni Medicina pro Praxi |
| Fakulta / Pracoviště MU | |
| Citace | |
| www | https://www.internimedicina.cz/pdfs/int/2019/02/11.pdf |
| Doi | http://dx.doi.org/10.36290/int.2019.044 |
| Klíčová slova | Dual inhibition; Heart failure; Sacubitril-valsartan |
| Popis | Dual antagonist of AT1 receptors for angiotensin II (ARB) and neprilysin, generic name sacubitril valsartan (formaly LCZ 696 or angiotensin receptor blocker and neprilysin inhibitor - ARNI) was clinicaly tested in the treatmet of hypertension and heart failure. The mechanism of action is in the blockade of AT1 receptros by valsartan in combination with decreased degradation of natriuretic peptides with increased vasodilatation. The first clinical trial PARAMOUNT with LCZ696 in the treatment of Heart failure patients with preserved ejection fraction has whown significant decrea-se of NT-proBNP concentrations. Clinical trial PARADIGM-HF in patients with decreased ejection fraction and high natriuretic peptides levels was fi-nished prematuraly for a positive effect of LCZ696 both on mortality and morbidity if compared with enalapril. Cardiovascular mortality was decreased by 20%, first hospitalisation for Heart failure by 21%. The PARAGON-HF study is testing the effect of sacubitril valsartan in patients with preserved ejection fraction |